Investor Board Members

About Lundbeckfonden Ventures

Lundbeckfonden Ventures is a part of the asset management subsidiary of The Lundbeck Foundation which in addition to substantial financial assets has controlling ownerships in H.Lundbeck A/S, ALK-Abelló A/S and Falck A/S. Lundbeckfonden Ventures has an evergreen structure and invests around $60 million annually. The Lundbeckfonden Ventures team is located in Copenhagen, Denmark, and is active in both Europe and US. For more information: www.lundbeckfondventures.com.

About Novartis Venture Funds

Founded in 1996, the Novartis Venture Funds currently manage over $800 million in committed capital. As a financially driven corporate life science investor, the Novartis Venture Funds invest in those companies which have the potential to address significant unmet medical needs critical to patient care. The Novartis Venture Funds’ team of ten investment professionals located in Basel Switzerland and Cambridge, MA brings together extensive expertise in the biotechnology, pharmaceutical and venture capital industries. For more information, visit: www.venturefund.novartis.com.

About SVLS

SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco. Formoreinformation,visit: www.svlsa.com.